Trial · NCT06905483
Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study
NCT06905483, Phase 4, Completed, Thammasat University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study. Trials, record NCT06905483. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06905483
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study
- NCT number
- NCT06905483
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 22 participants, actual
- Lead sponsor
- Thammasat University
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
- Interventions
- Budesonide/Glycopyrronium/Formoterol (BGF), Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
- First posted
- 2025-04-01
- Last updated
- 2026-02-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in airway resistance at 5 Hz (R5) on COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in R5 assessed by impulse oscillometry (IOS), reported as kPa/L/s and percent predicted value. |
| Primary | Changes in airway resistance at 20 Hz (R20) on COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in R20 assessed by impulse oscillometry (IOS), reported as kPa/L/s and percent predicted value. |
| Primary | Difference of airway resistance between 5 Hz and 20 Hz (R5-R20) on COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in R5-R20 assessed by impulse oscillometry (IOS), reported as kPa/L/s. |
| Primary | Reactance at 5 Hz (X5) on COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in X5 assessed by impulse oscillometry (IOS), reported as kPa/L/s. |
| Secondary | Changes in forced expiratory volume in 1 second (FEV1) in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in FEV1 assessed by spirometry, reported as liter (L) and percent predicted value. |
| Secondary | Changes in forced vital capacity (FVC) in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in FVC assessed by spirometry, reported as liter (L) and percent predicted value. |
| Secondary | Changes in FEV1/FVC ratio in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in FEV1/FVC ratio assessed by spirometry, reported as percent. |
| Secondary | Changes in forced expiratory flow at 25-75% of FVC (FEF25-75) in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in FEF25-75 assessed by spirometry, reported as liter/second (L/s) and percent predicted value. |
| Secondary | Changes in modified Medical Research Council dyspnea scale in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in this dyspnea scale are reported in points, with a minimum range of 0 and a maximum of 5. Higher scores indicate more symptoms. |
| Secondary | Changes in COPD assessment test score in COPD patients | From enrollment to the end of treatment at 8 weeks | Changes in this score are reported in points, with a minimum range of 0 and a maximum of 40. Higher scores indicate more symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06905483
GET https://conductscience.org/api/trials/v1/NCT06905483/registered